Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Kogenate (BAY14-2222)
Kogenate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Kogenate (BAY14-2222) | DRUG | 100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients. |
Inclusion Criteria: * Severe hemophilia A (FVIII:C \</=1%) * No history of FVIII inhibitor formation and no current evidence of inhibitor antibody (Bethesda Assay \< 0.6 BU) * Elective major surgery requiring at least 6 days of rFVIII-FS therapy * Subjects should have been previously treated with F...
Top 8 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 15 | PHASE3 | Concizumab, Mim8, Denecimig, NNC0442-0344 A, turoctocog alfa pegol |
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Fitusiran, efanesoctocog alfa |
| Pfizer Inc. | PFE | 8 | PHASE3 | Fidanacogene elaparvovec, Marstacimab |
| BioMarin Pharmaceutical Inc. | BMRN | 2 | PHASE3 | Valoctocogene roxaparvovec |
| Hoffmann-La Roche | RHHBY | 8 | PHASE3 | Emicizumab, NXT007, SPK-8011QQ, SPK-8011, SPK-8016 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | REGV131, LNP1265 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE1 | AskBio009 |
| Bayer | BAYRY | 6 | - | Damoctocog-alfa-pegol |
Kogenate is a hemophilia treatment developed by Bayer AG. It has been studied in a Phase 3 trial in hemophilia patients, specifically evaluating continuous infusion during surgeries. The completed study enrolled 15 male participants aged 12 years and older in Israel.
Kogenate is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor behind the clinical development program for this hemophilia therapy, including the Phase 3 study of continuous infusion in surgical settings.
Kogenate has been evaluated in a Phase 3 clinical trial. That study, NCT00606060, is completed. The program includes one trial total, with no active trials currently listed, and enrolled 15 participants.
Kogenate has been studied in one clinical trial, NCT00606060, titled BAY14-2222 Continuous Infusion in Surgeries. It was a Phase 3, completed, uncontrolled study that enrolled 15 male hemophilia patients aged 12 years and older in Israel.
Yes, Kogenate is also known as BAY14-2222. BAY14-2222 is the compound identifier used in the clinical trial record for Kogenate, the hemophilia therapy developed by Bayer AG. Both names refer to the same investigational asset.